Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 126 results for "julie masow"

Novartis investigational dual bronchodilator significantly imp...

/PRNewswire/ -- Today,Novartis announced for the first time detailed results from its phase III EXPEDITION trial program for QVA149 (indacaterol/glycopyrronium) in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD). In the ... Tamar Securities, 1 day ago

Alcon Study Reveals Nearly Half of Americans Would Avoid Reading Glasses If They Knew It Made Them Look Older

/PRNewswire/ -- According to a new survey conducted by Jacksonville University in Florida , one in four adults say reading glasses, also known as "readers," can make someone look ten years older.The survey, conducted in collaboration with Alcon, ...
 Market Pulse Navigator3 days ago

Amgen, Inc. Succeeds In Blocking Neupogen Biosimilar US Launch Yet Again

Amgen, Inc. ( NASDAQ:AMGN ) has succeeded yet again in its aggressive efforts aimed at preventing Sandoz, the generics drug unit of Novartis AG (ADR) ( NYSE:NVS ), from launching a biosimilar version of its blockbuster cancer drug Neupogen in the ...
 Bidness Etc2 weeks ago

Novartis Pharmaceuticals Corporation is first company to receive number one ranking two years in a row on DiversityInc Top 50 Companies for Diversity list

- Reflects clear plan to embed diversity and inclusion in every aspect of our business from the company culture to our strategic business focus EAST HANOVER, N.J., April 24, 2015 /PRNewswire/ --Novartis Pharmaceuticals Corporation (NPC) has been ...
 Fat Pitch Financials4 weeks ago

FDA approval of first generic multiple sclerosis drug will boost Momenta Pharmaceuticals

Federal regulators Thursday approved the first generic multiple sclerosis therapy, in a development that could drop the price of the drug for consumers and boost the business of Momenta Pharmaceuticals Inc., which developed the injectable treatment.
 Boston Globe1 month ago

AdverseEvents: Analysis of side-effect reports turns up troubling safety signals for Novartis, Eisai drugs

Drugs that treat brain-related diseases are often tied to troubling side effects, with companies listing everything from gambling compulsions and hypersexuality to mood changes and gastrointestinal bleeding on FDA-approved labels. Now an analysis of ...
 FiercePharma1 month ago

Novartis presents Cosentyx(tm) two-year efficacy and safety data showing

sustainable effect in psoriasis patients 03/21 06:04 CDT sustainable effect in psoriasis patients- New data at AAD shows 7 out of 10 psoriasis patients who were PASI 75 responders at 52 weeks achieved clear to almost clear skin (PASI 90) after ...
 Finwin2 months ago Novartis presents Cosentyx two-year efficacy and safety data showing sustainable effect in psoriasis patients  Tamar Securities2 months ago Novartis presents Cosentyx??? two-year efficacy and safety data showing sustainable effect in psoriasis patients  Review Seeker2 months ago Novartis presents Cosentyx„¢ two-year efficacy and safety data showing sustainable effect in psoriasis patients  TickerTech.com2 months ago

New Novartis data show more Cosentyx-treated psoriasis patients achieved clear or almost clear skin (PASI 90) compared to Stelara®

/PRNewswire/ --Novartis today announced results from the CLEAR study demonstrating Cosentyx (secukinumab) improved skin clearance at Week 16 in significantly more moderate-to-severe plaque psoriasis patients compared to Stelara ® * (ustekinumab), a ...
 Vision Monday2 months ago
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less